Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
about
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Outcomes of patients with sarc ...... mTOR, Her2, or MEK inhibitors.
@en
Outcomes of patients with sarc ...... mTOR, Her2, or MEK inhibitors.
@nl
type
label
Outcomes of patients with sarc ...... mTOR, Her2, or MEK inhibitors.
@en
Outcomes of patients with sarc ...... mTOR, Her2, or MEK inhibitors.
@nl
prefLabel
Outcomes of patients with sarc ...... mTOR, Her2, or MEK inhibitors.
@en
Outcomes of patients with sarc ...... mTOR, Her2, or MEK inhibitors.
@nl
P2093
P2860
P50
P1433
P1476
Outcomes of patients with sarc ...... mTOR, Her2, or MEK inhibitors
@en
P2093
Cynthia E Herzog
Daniel D Karp
David S Hong
Filip Janku
Funda Meric-Bernstam
Jennifer Wheler
Neeta Somaiah
Ralph Zinner
Robert S Benjamin
P2860
P2888
P356
10.1038/S41598-017-13114-8
P407
P577
2017-11-21T00:00:00Z